Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GPR183 | P32249 | 5/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905865 | 0.89 | GPR183 (0.63) | ALDH1A1HTTKDM4ETDP1GPR183 | |
| SCHEMBL2903325 | 0.89 | GPR183 (0.61) | ALDH1A1HTTKDM4ETDP1GPR183 | |
| SCHEMBL10300779 | 0.88 | MEN1 (0.64) | ALDH1A1HTTTDP1GPR183ACHE | |
| SCHEMBL2910147 | 0.87 | TDP1 (0.60) | ALDH1A1HTTKDM4ETDP1GPR183 | |
| SCHEMBL2906207 | 0.87 | TDP1 (0.57) | ALDH1A1HTTKDM4ETDP1GPR183 | |
| SCHEMBL2902830 | 0.84 | GPR183 (0.67) | TDP1GPR183ACHEMEN1KMT2A | |
| SCHEMBL10300778 | 0.84 | GPR183 (0.67) | TDP1GPR183ACHEMEN1KMT2A | |
| SCHEMBL16598995 | 0.83 | MEN1 (0.68) | ALDH1A1HTTGPR183FAAHACHE | |
| SCHEMBL16598998 | 0.83 | MEN1 (0.68) | ALDH1A1HTTGPR183FAAHACHE | |
| SCHEMBL2908746 | 0.83 | MEN1 (0.65) | TDP1GPR183MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PEREZ MICHEL (FR) | 2012-09-13 | — | — | US | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | claimed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | ALDH1A1 1137/4885HTT 2817/4885KDM4E 3494/4885 |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | ALDH1A1 1137/4885HTT 2817/4885KDM4E 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.